<DOC>
	<DOC>NCT01236235</DOC>
	<brief_summary>The purpose of this study is to describe long term (&gt; 96 weeks) efficacy and safety of Atazanavir-based regimens in real life setting.</brief_summary>
	<brief_title>Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting</brief_title>
	<detailed_description>Time perspective: Collection of historical data and longitudinal follow up. Patients will be enrolled in 2011/2012 but data will be collected from medical charts from ATV initiation date (Feb 2008 - July 2010) until July 2013 at the latest (if no ATV discontinuation, or death, or lost to follow up). Non probability sample: - Specialized HIV management centers will be contacted in order to recruit about 15-20 sites per country. - Each site will have to enroll an average of 8-12 consecutive patients (min:5; max:30) fulfilling the inclusion/exclusion criteria.</detailed_description>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Male or Female HIV patients ≥ 18 years old at ATV/RTV initiation treatment date Outpatient seen in routine consultation whatever the reason, between January 1st 2011 and March 31st 2012 Commencing an ATV/RTVbased regimen including at least 2 nucleoside reverse transcriptase inhibitors (NRTI) after February 1st 2008 and before July 31st 2010, regardless of the current ARV treatment ongoing at enrollment visit Patient exposed to or who began ATV/RTV prior to February 1st 2008, or after July 31st 2010 or without a known start date for ATV/RTV therapy Exposure to more than 4 weeks of any ARV prior to initiation of ATV/RTV treatment Participation in a clinical trial with ATV at the time of or after initiation of ATV/RTVbased regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>